Trial data on retatrutide is super promising, and the grey market seems to have lost interest in first-to-market GLP-1 Ozempic
She was on a DMARD and a biologic both at full doses and still having multiple flares per month
How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test may help provide context by revealing predispositions in GLP-1 receptor (rs6923761), GIPR (rs1800437), and metabolic pathways (FTO rs9939609, MC4R rs17782313)
Tracy Norfleet, MD, FACP, advises: "Injection site may be infected if you notice redness, warmth, or tenderness or swelling in the area, and it keeps getting worse or lasts more than 1 to 2 days." Here are specific signs that should prompt you to consult your doctor: Pus or discharge coming from the injection site Warmth spreading beyond the immediate area Red streaking extending outward from the injection site Redness or swelling larger than 2 inches in diameter Hardened lumps that dont go away, suggesting a possible infection Severe pain that disrupts your daily activities Reactions lasting more than a week Unusual skin discoloration Fever accompanied by chills New lumps or swelling in your neck, especially with hoarseness or difficulty swallowing If any of these symptoms appear, dont delay contacting your healthcare provider
Retatrutide is not approved by Health Canada or the FDA as of March 2026
Based on Phase 2 clinical trials, patients with T2DM who were inadequately managed with diet and exercise alone or were on a stable metformin regimen for at least 3 months before screening received once-weekly subcutaneous injections of tirzepatide at doses of 1 mg, 5 mg, 10 mg, or 15 mg for 26 weeks
